In a recent 13F filing, major healthcare investor OrbiMed Advisors revealed it had liquidated its entire stake in Danaher Corp. during the second quarter of 2026. The filing, which reflects trades made by June 30, showed the sale of all 265,800 shares, valued at approximately $50.4 million at the end of the prior quarter. This move marked a complete exit from a position that had previously accounted for about 1% of OrbiMed's reported portfolio.
This disclosure is from a delayed quarterly report and does not represent a real-time trade. The sale followed a period where Danaher's stock fell despite beating Q2 earnings expectations. OrbiMed had already signaled a reduction in its conviction, having trimmed its stake by over 11% in the first quarter of 2026. The firm has not publicly commented on its reason for the complete exit.